Sodium‐glucose co‐transporter‐2 inhibitors and the risk of urosepsis: A multi‐site, prevalent new‐user cohort study-Reference-Cited by-同舟云学术

Sodium‐glucose co‐transporter‐2 inhibitors and the risk of urosepsis: A multi‐site, prevalent new‐user cohort study

Published:2020-06-04 Issue:9 Volume:22 Page:1648-1658
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Fisher Anat¹,Fralick Michael²³^ORCID,Filion Kristian B.⁴⁵^ORCID,Dell'Aniello Sophie⁵,Douros Antonios⁴⁵⁶^ORCID,Tremblay Éric⁷,Shah Baiju R.³⁸⁹,Ronksley Paul E.¹⁰,Alessi‐Severini Silvia¹¹¹²,Hu Nianping¹³,Bugden Shawn C.¹¹¹⁴,Ernst Pierre⁵¹⁵,Lix Lisa M.¹⁶^ORCID,

Affiliation:

1. Department of Anesthesiology, Pharmacology and TherapeuticsUniversity of British Columbia Vancouver British Columbia Canada

2. Sinai Health System Toronto Ontario Canada

3. Department of MedicineUniversity of Toronto Toronto Ontario Canada

4. Departments of Medicine and Epidemiology, Biostatistics and Occupational HealthMcGill University Montreal Québec Canada

5. Centre for Clinical EpidemiologyLady Davis Institute Montreal Québec Canada

6. Institute of Clinical Pharmacology and Toxicology, Charité‐Universitätsmedizin Berlin Berlin Germany

7. Institut National d'Excellence en Santé et en Services Sociaux (INESSS) Quebec City Quebec Canada

8. ICES Toronto Ontario Canada

9. Department of MedicineDivision of Endocrinology and Metabolism, Sunnybrook Health Sciences Centre Toronto Ontario Canada

10. Department of Community Health Sciences, Cumming School of MedicineUniversity of Calgary Calgary Alberta Canada

11. College of Pharmacy, Rady Faculty of Health SciencesUniversity of Manitoba Winnipeg Manitoba Canada

12. Manitoba Centre for Health Policy, Rady Faculty of Health SciencesUniversity of Manitoba Winnipeg Manitoba Canada

13. The Health Quality Council Saskatoon Saskatchewan Canada

14. School of PharmacyMemorial University of Newfoundland St John's Newfoundland and Labrador Canada

15. Department of MedicineMcGill University Montreal Quebec Canada

16. Department of Community Health SciencesUniversity of Manitoba Winnipeg Manitoba Canada

Funder

Canadian Institutes of Health Research

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14082

Reference40 articles.

1. U.S. Food and Drug Administration (FDA). FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Available athttp://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about. Accessed December 3 2019.

2. U.S. Food and Drug Administration (FDA). FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. Available athttp://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes. Accessed December 3 2019.

3. An update on SGLT2 inhibitors for the treatment of diabetes mellitus;Hsia DS;Curr Opin Endocrinol Diabetes Obes.,2017

4. U.S. Food and Drug Administration (FDA). Questions and answers on FDA's adverse event reporting system (FAERS). Available athttp://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers. Accessed January 3 2020.

5. Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparators in Pharmacovigilance: A Quasi-Quantification Bias Analysis;Drug Safety;2024-05-04

2. Principles of Pharmacovigilance and Drug Regulation;Principles and Practice of Pharmacovigilance and Drug Safety;2024

3. A case of emphysematous pyelonephritis in an older man with poorly controlled type 2 diabetes mellitus;CEN Case Reports;2023-09-22

4. Asymptomatic pyuria and bacteriuria are not risk factors for urinary tract infection in women with type 2 diabetes mellitus initiated SGLT2 inhibitors;International Urology and Nephrology;2023-09-16

5. Medications Associated with Occurrence of Urinary Tract Infections in Patients with Diabetes, Heart Failure or Both;Current Drug Safety;2023-08